Floatz logo

Pixantrone

Solid Tumor (Excluding CNS)

CTI BioPharmaSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Solid Tumor (Excluding CNS) cohort.

Asset / SponsorPhaseRating
Sc-Car.Gpc3Xil15.21 Car T Cells
Seattle Children's Hospital
Phase 1CC

Same molecule, other indications

Pixantrone is also rated in:

follicular lymphomaDormant
BB
Indicative ·
65 / 100
View asset →
Lymphoma, Mixed-Cell, FollicularDormant
BB
Indicative ·
65 / 100
View asset →
Lymphoma, Low-GradeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →